GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01825148

Acronym

GLP-1-CPOP

Enrollment

Registered

2013-04-05

Start date

2012-12-31

Completion date

2014-05-31

Last updated

2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Diabetes

Brief summary

The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.

Interventions

OTHERradiolabeled Exendin

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* type 1 Diabetes

Exclusion criteria

* breast feeding * pregnant

Design outcomes

Primary

Measure	Time frame	Description
pancreatic uptake of radiolabeled Exendin	7 days	uptake will be given as counts per MBq injected activity as determined by calibrated SPECT/CT scanner with attenuation correction.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026